Published in Cancer Res on June 01, 2005
Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer (2010) 5.26
Competition amongst Eph receptors regulates contact inhibition of locomotion and invasiveness in prostate cancer cells. Nat Cell Biol (2010) 1.89
The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer (2007) 1.78
The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood (2005) 1.56
Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis. Adv Cancer Res (2012) 1.17
Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth. Am J Pathol (2010) 1.15
Investigation of the expression of the EphB4 receptor tyrosine kinase in prostate carcinoma. BMC Cancer (2005) 1.12
The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood (2008) 1.09
The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. Angiogenesis (2010) 1.08
Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor. Biochem J (2009) 1.06
Profiling Eph receptor expression in cells and tissues: a targeted mass spectrometry approach. Cell Adh Migr (2012) 1.02
Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther (2010) 1.02
Soluble EphB4 inhibition of PDGF-induced RPE migration in vitro. Invest Ophthalmol Vis Sci (2009) 1.00
Generation of human-induced pluripotent stem cells to model spinocerebellar ataxia type 2 in vitro. J Mol Neurosci (2012) 0.96
Targeting the EphB4 receptor for cancer diagnosis and therapy monitoring. Mol Pharm (2012) 0.90
Eph and ephrins in epithelial stem cell niches and cancer. Cell Adh Migr (2012) 0.90
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. PLoS One (2013) 0.90
EphB4 as a therapeutic target in mesothelioma. BMC Cancer (2013) 0.84
The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder. PLoS One (2014) 0.83
Regulation of contact inhibition of locomotion by Eph-ephrin signalling. J Microsc (2013) 0.83
Increased expression of EphA1 protein in prostate cancers correlates with high Gleason score. Int J Clin Exp Pathol (2013) 0.82
The tumour-promoting receptor tyrosine kinase, EphB4, regulates expression of integrin-β8 in prostate cancer cells. BMC Cancer (2015) 0.81
Modeling error in experimental assays using the bootstrap principle: understanding discrepancies between assays using different dispensing technologies. J Comput Aided Mol Des (2015) 0.80
Over-expression of Ephb4 is associated with carcinogenesis of gastric cancer. Dig Dis Sci (2010) 0.79
EphB4-targeted imaging with antibody h131, h131-F(ab')2 and h131-Fab. Mol Pharm (2013) 0.79
Changes in gene-expression profiles of colon carcinoma cells induced by wild type K-ras2. World J Gastroenterol (2007) 0.78
Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4. Biochem Pharmacol (2012) 0.77
Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition. Growth Factors (2014) 0.76
The role of EphB4 and IGF-IR expression in breast cancer cells. Int J Clin Exp Pathol (2015) 0.76
Overexpression of erythropoietin-producing hepatocyte receptor B4 and ephrin-B2 is associated with estrogen receptor expression in endometrial adenocarcinoma. Oncol Lett (2017) 0.75
Membrane-mediated regulation of vascular identity. Birth Defects Res C Embryo Today (2016) 0.75
Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas. Sci Rep (2016) 0.75
Anti-tumour effects of antibodies targeting the extracellular cysteine-rich region of the receptor tyrosine kinase EphB4. Oncotarget (2015) 0.75
KSR1 and EPHB4 Regulate Myc and PGC1β To Promote Survival of Human Colon Tumors. Mol Cell Biol (2016) 0.75
Pten and EphB4 regulate the establishment of perisomatic inhibition in mouse visual cortex. Nat Commun (2016) 0.75
Loss of the EPH receptor B6 contributes to colorectal cancer metastasis. Sci Rep (2017) 0.75
International network of cancer genome projects. Nature (2010) 20.35
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer (2009) 5.89
Cyclin D as a therapeutic target in cancer. Nat Rev Cancer (2011) 5.76
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol (2011) 3.59
Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci U S A (2010) 2.67
Urinary diversion. Urology (2007) 2.65
Benign retroperitoneal schwannoma: a case series and review of the literature. Urology (2003) 2.62
Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol (2006) 2.55
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol (2004) 2.50
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol (2012) 2.48
Randomized controlled trial of collaborative care management of depression among low-income patients with cancer. J Clin Oncol (2008) 2.47
Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur Urol (2011) 2.31
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol (2012) 2.31
Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A (2003) 2.31
Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS One (2007) 2.26
Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol (2013) 2.26
Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res (2006) 2.23
Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol (2009) 2.21
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19
Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat (2003) 2.14
Resection of the inferior vena cava without reconstruction for urologic malignancies. Urology (2009) 2.08
Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium. Proc Natl Acad Sci U S A (2008) 2.07
Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol (2006) 2.01
Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood (2007) 2.01
Null association between histology of first and second primary malignancies in men with bilateral testicular germ cell tumors. Am J Epidemiol (2013) 2.00
Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol (2004) 2.00
Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res (2009) 1.98
A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol (2003) 1.96
The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study. Cancer Epidemiol Biomarkers Prev (2007) 1.95
Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol (2009) 1.94
Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol (2006) 1.92
Regional activation of the cancer genome by long-range epigenetic remodeling. Cancer Cell (2012) 1.91
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer (2010) 1.89
Sphingosine kinase mediates vascular endothelial growth factor-induced activation of ras and mitogen-activated protein kinases. Mol Cell Biol (2002) 1.85
Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol (2006) 1.83
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res (2003) 1.81
Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol (2013) 1.81
DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol (2002) 1.78
Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol (2009) 1.78
Robotic intracorporeal orthotopic ileal neobladder: replicating open surgical principles. Eur Urol (2012) 1.76
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol (2012) 1.76
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol (2011) 1.75
Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction. Urol Clin North Am (2005) 1.74
Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer (2005) 1.73
Cell cycle control in breast cancer cells. J Cell Biochem (2006) 1.68
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol (2012) 1.66
Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. Eur Urol (2012) 1.65
Lymph node dissection technique is more important than lymph node count in identifying nodal metastases in radical cystectomy patients: a comparative mapping study. Eur Urol (2011) 1.65
Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res (2004) 1.65
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology (2010) 1.65
Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res (2010) 1.62
Identification of Hendra virus G glycoprotein residues that are critical for receptor binding. J Virol (2007) 1.61
Aberration in the expression of the retinoid receptor, RXRalpha, in prostate cancer. Cancer Biol Ther (2003) 1.58
Long-term outcomes of open radical retropubic prostatectomy for clinically localized prostate cancer in the prostate-specific antigen era. Urology (2012) 1.58
Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol (2008) 1.58
The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood (2005) 1.56
Outcomes of transperineal template-guided prostate biopsy in 409 patients. BJU Int (2013) 1.55
Radical cystectomy in the elderly: Comparison of survival between younger and older patients. Cancer (2005) 1.55
Molecular markers of prostate cancer outcome. Eur J Cancer (2005) 1.52
York Mason procedure to repair iatrogenic rectourinary fistula: our experience. World J Surg (2013) 1.52
An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res (2005) 1.52
Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program. Cancer (2013) 1.51
Venous resection in urological surgery. J Urol (2008) 1.50
Factors influencing the choice of urinary diversion in patients undergoing radical cystectomy. BJU Int (2010) 1.48
Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clin Cancer Res (2005) 1.48
Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos. Blood (2008) 1.47
Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. Cancer (2003) 1.47